Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-10-25 21:29 | English | 2.5 KB | |||
| 2011-10-15 00:22 |
WILEX AG reports an adjustment of the goodwill of Heidelberg Pharma AG accordin…
|
English | 6.9 KB | ||
| 2011-10-13 07:05 |
WILEX AG publishes 9-month financial report 2011
|
English | 27.7 KB | ||
| 2011-10-10 07:56 |
WILEX AG: WILEX Inc. and ALPCO Diagnostics sign marketing and distribution agre…
|
English | 9.3 KB | ||
| 2011-10-05 07:48 |
WILEX AG: FDA grants Fast Track designation to WILEX's RENCAREX(R) for the adju…
|
English | 10.6 KB | ||
| 2011-09-15 10:34 |
WILEX AG: WILEX starts first oral Phase I study with MEK inhibitor WX-554
|
English | 7.7 KB | ||
| 2011-08-03 08:34 |
WILEX's subsidiary WILEX Inc. receives ISO certification
|
English | 8.9 KB | ||
| 2011-07-14 07:03 |
WILEX AG announces successful half year results
|
English | 25.7 KB | ||
| 2011-06-17 07:25 |
WILEX AG: WILEX and IBA report on the Pre-BLA Meeting with the FDA and the next…
|
English | 13.3 KB | ||
| 2011-06-17 00:13 |
WILEX AG reports on the Pre-BLA Meeting with the FDA and the next steps in the …
|
English | 7.8 KB | ||
| 2011-05-05 07:15 |
WILEX AG: Patient recruitment in Phase II breast cancer trial with MESUPRON(R) …
|
English | 10.3 KB | ||
| 2011-05-02 06:55 |
WILEX AG grants exclusive US commercialisation rights for RENCAREX(R) to Promet…
|
English | 12.0 KB | ||
| 2011-04-30 00:16 |
WILEX AG grants exclusive US commercialisation rights for RENCAREX(R) to
|
English | 7.7 KB | ||
| 2011-04-13 07:18 |
WILEX AG publishes financial report for the first quarter of 2011
|
English | 20.3 KB | ||
| 2011-04-13 00:00 |
Q1 Report 2010/2011
|
German | 821.7 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
